The long-term risk of tuberculosis among individuals with Xpert Ultra "trace" screening results: a longitudinal follow-up study.

Joowhan Sung, Mariam Nantale, Annet Nalutaaya, Patrick Biché, James Mukiibi, Joab Akampurira, Rogers Kiyonga, Francis Kayondo, Michael Mukiibi, Caitlin Visek, Caleb E Kamoga, David W Dowdy, Achilles Katamba, Emily A Kendall
{"title":"The long-term risk of tuberculosis among individuals with Xpert Ultra \"trace\" screening results: a longitudinal follow-up study.","authors":"Joowhan Sung, Mariam Nantale, Annet Nalutaaya, Patrick Biché, James Mukiibi, Joab Akampurira, Rogers Kiyonga, Francis Kayondo, Michael Mukiibi, Caitlin Visek, Caleb E Kamoga, David W Dowdy, Achilles Katamba, Emily A Kendall","doi":"10.1101/2025.03.20.25324205","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Systematic screening for tuberculosis using Xpert Ultra generates \"trace\" results of uncertain significance. Additional microbiological testing in this context is often negative, but individuals with trace results might have early disease or elevated risk of tuberculosis.</p><p><strong>Methods: </strong>We screened for tuberculosis with Xpert Ultra in Uganda, enrolling individuals with trace-positive results and Ultra-negative controls. Participants without tuberculosis on extensive initial evaluation were followed, with repeat testing at 1, 3, and 6 months after trace results, and at 12 and 24 months for all participants. We estimated cumulative cause-specific hazards of incident tuberculosis, considering a definition of tuberculosis that included clinician judgment and one based strictly on microbiological results. We compared participants with Ultra-trace versus Ultra-negative sputum, and subgroups of participants with Ultra-trace sputum.</p><p><strong>Findings: </strong>Of 129 participants with trace-positive screening results, 45 (35%) were recommended for treatment upon enrollment, and eight were lost to follow-up within three months. Of 76 remaining participants followed for median 697 (interquartile range 179-714) days, 20 (26%) were recommended for tuberculosis treatment. The cumulative hazard of clinician-defined incident tuberculosis was 26% (95% confidence interval: 14-38%) at one year and 35% (19-52%) at two years, versus 2% (0-5%) at two years for controls. Hazards were similar for microbiologically defined incident tuberculosis. Incident tuberculosis was strongly associated with abnormal baseline chest X-ray (hazard ratio 15.0 [3.4-65.1]) but not with baseline symptoms.</p><p><strong>Interpretation: </strong>Individuals with trace-positive sputum during screening, particularly those with abnormal chest imaging, are at substantial risk of incident tuberculosis over the subsequent two years.</p><p><strong>Funding: </strong>National Institutes of Health.</p><p><strong>Research in context: </strong><b>Evidence before this study:</b> Recent advances in tuberculosis research have shifted the disease framework from a binary classification of latent versus active tuberculosis to a continuum of disease states. They have also led to a better understanding of the dynamic disease course of early tuberculosis, which can either progress to culture-positive disease or regress spontaneously over time. \"Trace\" results from Xpert MTB/RIF Ultra (\"Ultra\") are sometimes perceived as false positives in individuals who subsequently test negative on additional diagnostic assays. However, some of these individuals may have early tuberculosis that falls below the detection threshold of existing diagnostic tests and could progress to microbiologically detectable disease over time. To investigate this, we searched PubMed for studies published up to February 7, 2025, using the terms \"tuberculosis\" AND (\"Xpert OR \"Xpert Ultra\" OR \"Ultra\") AND \"Trace\" and also reviewed the reference lists of relevant search results. Two prevalence surveys that used Xpert Ultra as a confirmatory test for individuals with symptoms or an abnormal chest X-ray found that 20% and 46% of those with trace-positive sputum had positive cultures. In a study conducted in Uganda where Ultra was used as an initial screening test, only 14% of individuals with a trace-positive result had positive sputum cultures. However, no prior studies have prospectively examined the incidence of tuberculosis among individuals with a trace-positive Ultra result during systematic screening who are otherwise microbiologically negative and not started on treatment.<b>Added value of this study:</b> In this study, individuals with Ultra trace-positive screening results who were not started on treatment after extensive diagnostic testing were followed for up to two years with repeated testing. About 25% developed tuberculosis during follow-up, and the 2-year cumulative hazard of incident tuberculosis was substantial at 35% (95% confidence interval 19-52%). Those who had a normal chest X-ray at enrollment were at significantly lower risk of developing tuberculosis. Incident tuberculosis risk was similar between those who reported symptoms at the time of enrollment and those who did not.<b>Implications of all the available evidence:</b> The high incidence of tuberculosis observed among people with trace results in this study support provision of treatment to most individuals who receive trace results during tuberculosis screening. These results also demonstrate that X-ray could be a useful tool to guide treatment decision-making for individuals with trace-positive sputum.</p>","PeriodicalId":94281,"journal":{"name":"medRxiv : the preprint server for health sciences","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11957171/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv : the preprint server for health sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2025.03.20.25324205","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Systematic screening for tuberculosis using Xpert Ultra generates "trace" results of uncertain significance. Additional microbiological testing in this context is often negative, but individuals with trace results might have early disease or elevated risk of tuberculosis.

Methods: We screened for tuberculosis with Xpert Ultra in Uganda, enrolling individuals with trace-positive results and Ultra-negative controls. Participants without tuberculosis on extensive initial evaluation were followed, with repeat testing at 1, 3, and 6 months after trace results, and at 12 and 24 months for all participants. We estimated cumulative cause-specific hazards of incident tuberculosis, considering a definition of tuberculosis that included clinician judgment and one based strictly on microbiological results. We compared participants with Ultra-trace versus Ultra-negative sputum, and subgroups of participants with Ultra-trace sputum.

Findings: Of 129 participants with trace-positive screening results, 45 (35%) were recommended for treatment upon enrollment, and eight were lost to follow-up within three months. Of 76 remaining participants followed for median 697 (interquartile range 179-714) days, 20 (26%) were recommended for tuberculosis treatment. The cumulative hazard of clinician-defined incident tuberculosis was 26% (95% confidence interval: 14-38%) at one year and 35% (19-52%) at two years, versus 2% (0-5%) at two years for controls. Hazards were similar for microbiologically defined incident tuberculosis. Incident tuberculosis was strongly associated with abnormal baseline chest X-ray (hazard ratio 15.0 [3.4-65.1]) but not with baseline symptoms.

Interpretation: Individuals with trace-positive sputum during screening, particularly those with abnormal chest imaging, are at substantial risk of incident tuberculosis over the subsequent two years.

Funding: National Institutes of Health.

Research in context: Evidence before this study: Recent advances in tuberculosis research have shifted the disease framework from a binary classification of latent versus active tuberculosis to a continuum of disease states. They have also led to a better understanding of the dynamic disease course of early tuberculosis, which can either progress to culture-positive disease or regress spontaneously over time. "Trace" results from Xpert MTB/RIF Ultra ("Ultra") are sometimes perceived as false positives in individuals who subsequently test negative on additional diagnostic assays. However, some of these individuals may have early tuberculosis that falls below the detection threshold of existing diagnostic tests and could progress to microbiologically detectable disease over time. To investigate this, we searched PubMed for studies published up to February 7, 2025, using the terms "tuberculosis" AND ("Xpert OR "Xpert Ultra" OR "Ultra") AND "Trace" and also reviewed the reference lists of relevant search results. Two prevalence surveys that used Xpert Ultra as a confirmatory test for individuals with symptoms or an abnormal chest X-ray found that 20% and 46% of those with trace-positive sputum had positive cultures. In a study conducted in Uganda where Ultra was used as an initial screening test, only 14% of individuals with a trace-positive result had positive sputum cultures. However, no prior studies have prospectively examined the incidence of tuberculosis among individuals with a trace-positive Ultra result during systematic screening who are otherwise microbiologically negative and not started on treatment.Added value of this study: In this study, individuals with Ultra trace-positive screening results who were not started on treatment after extensive diagnostic testing were followed for up to two years with repeated testing. About 25% developed tuberculosis during follow-up, and the 2-year cumulative hazard of incident tuberculosis was substantial at 35% (95% confidence interval 19-52%). Those who had a normal chest X-ray at enrollment were at significantly lower risk of developing tuberculosis. Incident tuberculosis risk was similar between those who reported symptoms at the time of enrollment and those who did not.Implications of all the available evidence: The high incidence of tuberculosis observed among people with trace results in this study support provision of treatment to most individuals who receive trace results during tuberculosis screening. These results also demonstrate that X-ray could be a useful tool to guide treatment decision-making for individuals with trace-positive sputum.

背景:使用 Xpert Ultra 对结核病进行系统筛查会产生意义不确定的 "微量 "结果。在这种情况下,额外的微生物检测通常是阴性的,但有微量结果的人可能患有早期疾病或结核病风险升高:方法:我们在乌干达用 Xpert Ultra 进行了结核病筛查,纳入了痕量阳性结果者和 Ultra 阴性对照者。我们对初次广泛评估时未发现结核病的参与者进行了随访,并在痕量结果出现后的 1、3 和 6 个月以及所有参与者出现痕量结果后的 12 和 24 个月进行了重复检测。我们估算了肺结核发病的累积特异性病因危险度,考虑了包括临床医生判断在内的肺结核定义和严格基于微生物学结果的定义。我们比较了痰液为超痕量和超阴性的参与者,以及痰液为超痕量的参与者亚组:在筛查结果为痕量阳性的 129 名参与者中,有 45 人(35%)在注册时被建议接受治疗,8 人在三个月内失去了随访机会。其余 76 名参与者的随访天数中位数为 697 天(四分位数间距为 179-714 天),其中 20 人(26%)被建议接受结核病治疗。临床医生定义的肺结核发病累积危险度在一年时为 26%(95% 置信区间:14-38%),两年时为 35%(19-52%),而对照组在两年时为 2%(0-5%)。微生物学定义的结核病发病风险与对照组相似。肺结核与基线胸部 X 光片异常密切相关(危险比为 15.0 [3.4-65.1]),但与基线症状无关:解释:筛查期间痰液呈痕量阳性的人,尤其是胸部X光检查异常的人,在随后的两年中患结核病的风险很大:研究背景:美国国立卫生研究院:本研究之前的证据:结核病研究的最新进展已将疾病框架从潜伏结核病与活动性结核病的二元分类法转变为疾病状态的连续统一体。这些研究还使人们对早期结核病的动态病程有了更好的了解,随着时间的推移,早期结核病既可能发展为培养阳性疾病,也可能自然消退。Xpert MTB/RIF Ultra("Ultra")的 "微量 "检测结果有时会被认为是假阳性,因为这些人随后在其他诊断检测中检测结果为阴性。然而,其中一些人可能患有早期结核病,但低于现有诊断检测的检测阈值,随着时间的推移,可能发展为微生物可检测的疾病。为了研究这个问题,我们在 PubMed 上搜索了截至 2025 年 2 月 7 日发表的研究,搜索时使用了 "结核病 "和("Xpert 或 "Xpert Ultra" 或 "Ultra")以及 "痕量 "等词,并查阅了相关搜索结果的参考文献列表。两项使用 Xpert Ultra 作为对有症状或胸部 X 光片异常者进行确诊检测的患病率调查发现,20% 和 46% 的痕量阳性痰培养呈阳性。在乌干达进行的一项研究中,Ultra 被用作初筛检测,结果显示只有 14% 的痕量阳性患者痰培养呈阳性。然而,此前没有任何研究对系统筛查中 Ultra 检测结果呈痕量阳性但微生物学检测结果为阴性且未开始接受治疗的患者的结核病发病率进行过前瞻性研究:在这项研究中,我们对 Ultra 检测结果呈痕量阳性、但经过大量诊断检测后仍未开始治疗的患者进行了长达两年的重复检测。在随访期间,约有 25% 的人患上了肺结核,2 年的累计肺结核发病率高达 35%(95% 置信区间为 19-52%)。入组时胸部 X 光片正常者罹患肺结核的风险明显较低。在入组时报告症状的人与未报告症状的人患肺结核的风险相似:本研究中观察到的微量结果显示肺结核的高发病率支持为大多数在肺结核筛查中得到微量结果的人提供治疗。这些结果还表明,X 射线是指导痰液呈微量阳性者做出治疗决策的有用工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信